Herceptin

Herceptin
Name	Herceptin

Herceptin is a monoclonal antibody that interferes with the HER2/neu receptor, which is associated with breast cancer, particularly in patients with invasive ductal carcinoma and inflammatory breast cancer. Its development is attributed to the work of Dennis Slamon, Axel Ullrich, and H. Michael Shepard, who collaborated with Genentech to create the drug. Herceptin has been used in conjunction with chemotherapy and hormone therapy to treat patients with metastatic breast cancer, including those with trastuzumab-resistant tumors, as seen in the HERA trial conducted by the Breast International Group.

Introduction

Herceptin is used to treat patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for approximately 20% of all breast cancer cases, including ductal carcinoma in situ and lobular carcinoma in situ. The drug is often administered in combination with paclitaxel and carboplatin to patients with early-stage breast cancer, as demonstrated in the BCIRG 006 trial conducted by the Breast Cancer International Research Group. Herceptin has also been investigated as a potential treatment for other types of cancer, including gastric cancer and esophageal cancer, in collaboration with researchers from the National Cancer Institute and the American Cancer Society. The development of Herceptin has been recognized with numerous awards, including the Lasker-DeBakey Clinical Medical Research Award and the Warren Alpert Foundation Prize.

Mechanism_of_action

Herceptin works by binding to the HER2/neu receptor, which is overexpressed in certain types of breast cancer cells, including those with amplified HER2 genes. This binding inhibits the proliferation of cancer cells and induces apoptosis, or programmed cell death, as demonstrated in studies by Robert Weinberg and Charles Sawyers. Herceptin also recruits immune cells, such as natural killer cells and macrophages, to attack cancer cells, as shown in research by James Allison and Tasuku Honjo. The mechanism of action of Herceptin is similar to that of other monoclonal antibodies, such as rituximab and cetuximab, which target different receptors, including the CD20 and EGFR receptors, respectively.

Medical_uses

Herceptin is approved for the treatment of patients with HER2-positive breast cancer, including those with early-stage breast cancer and metastatic breast cancer. The drug is often used in combination with chemotherapy and hormone therapy to treat patients with invasive ductal carcinoma and inflammatory breast cancer, as demonstrated in the NSABP B-31 trial conducted by the National Surgical Adjuvant Breast and Bowel Project. Herceptin has also been investigated as a potential treatment for other types of cancer, including gastric cancer and esophageal cancer, in collaboration with researchers from the European Organisation for Research and Treatment of Cancer and the American Society of Clinical Oncology. The use of Herceptin has been recognized by the National Comprehensive Cancer Network and the European Society for Medical Oncology.

Side_effects

The most common side effects of Herceptin include infusion reactions, fever, chills, and nausea, as reported in studies by Larry Norton and Clifford Hudis. Herceptin can also cause cardiotoxicity, including heart failure and left ventricular dysfunction, as demonstrated in research by Sandra Swain and Eric Winer. Patients receiving Herceptin should be monitored for signs of cardiac dysfunction, including ejection fraction and left ventricular ejection fraction, as recommended by the American Heart Association and the European Society of Cardiology. The side effects of Herceptin are similar to those of other monoclonal antibodies, such as bevacizumab and ipilimumab, which target different receptors, including the VEGF and CTLA-4 receptors, respectively.

History

Herceptin was first approved by the US Food and Drug Administration in 1998 for the treatment of patients with metastatic breast cancer. The development of Herceptin is attributed to the work of Dennis Slamon, Axel Ullrich, and H. Michael Shepard, who collaborated with Genentech to create the drug. Herceptin has since been approved for the treatment of patients with early-stage breast cancer and has been recognized with numerous awards, including the Lasker-DeBakey Clinical Medical Research Award and the Warren Alpert Foundation Prize. The history of Herceptin is closely tied to the development of other monoclonal antibodies, including rituximab and cetuximab, which were developed by researchers from the University of California, San Francisco and the Memorial Sloan Kettering Cancer Center.

Pharmacology

Herceptin is a monoclonal antibody that is administered via intravenous infusion. The drug has a half-life of approximately 28 days and is eliminated primarily through hepatic metabolism, as demonstrated in studies by William Dalton and George P. Rodgers. Herceptin can be used in combination with other chemotherapy agents, including paclitaxel and carboplatin, to treat patients with breast cancer, as shown in research by Gabriel Hortobagyi and Larry Norton. The pharmacology of Herceptin is similar to that of other monoclonal antibodies, such as bevacizumab and ipilimumab, which target different receptors, including the VEGF and CTLA-4 receptors, respectively. The development of Herceptin has been recognized by the National Academy of Sciences and the Institute of Medicine.

Category:Monoclonal antibodies